Cortico-hippocampal hyperexcitability in synapsin I/II/III knockout mice: age-dependency and response to the antiepileptic drug levetiracetam

Neuroscience. 2010 Nov 24;171(1):268-83. doi: 10.1016/j.neuroscience.2010.08.046. Epub 2010 Sep 16.

Abstract

Synapsins (SynI, SynII, SynIII) are a multigene family of synaptic vesicle (SV) phosphoproteins implicated in the regulation of synaptic transmission and plasticity. Synapsin I, II, I/II and I/II/III knockout mice are epileptic and SYN1/2 genes have been identified as major epilepsy susceptibility genes in humans. We analyzed cortico-hippocampal epileptiform activity induced by 4-aminopyridine (4AP) in acute slices from presymptomatic (3-weeks-old) and symptomatic (1-year-old) Syn I/II/III triple knockout (TKO) mice and aged-matched triple wild type (TWT) controls and assessed the effect of the SV-targeted antiepileptic drug (AED) levetiracetam (LEV) in reverting the epileptic phenotype. Both fast and slow interictal (I-IC) and ictal (IC) events were observed in both genotypes. The incidence of fast I-IC events was higher in presymptomatic TKO slices, while frequency and latency of I-IC events were similar in both genotypes. The major age and genotype effects were observed in IC activity, that was much more pronounced in 3-weeks-old TKO and persisted with age, while it disappeared from 1-year-old TWT slices. LEV virtually suppressed fast I-IC and IC discharges from 3-weeks-old TWT slices, while it only increased the latency of fast I-IC and IC activity in TKO slices. Analysis of I-IC events in patch-clamped CA1 pyramidal neurons revealed that LEV increased the inhibitory/excitatory ratio of I-IC activity in both genotypes. The lower LEV potency in TKO slices of both ages was associated with a decreased expression of SV2A, a SV protein acting as LEV receptor, in cortex and hippocampus. The results demonstrate that deletion of Syn genes is associated with a higher propensity to 4AP-induced epileptic paroxysms that precedes the onset of epilepsy and consolidates with age. LEV ameliorates such hyper excitability by enhancing the inhibition/excitation ratio, although the effect is hindered in TKO slices which exhibit a concomitant decrease in the levels of the LEV receptor SV2A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Aminopyridine / pharmacology
  • Aging*
  • Analysis of Variance
  • Animals
  • Anticonvulsants / pharmacology*
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / pathology
  • Cerebral Cortex / physiopathology*
  • Disease Models, Animal
  • Drug Interactions
  • Electrodes
  • Epilepsy, Tonic-Clonic / genetics
  • Epilepsy, Tonic-Clonic / pathology*
  • Evoked Potentials / drug effects
  • Evoked Potentials / genetics
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / genetics
  • Hippocampus / pathology
  • Hippocampus / physiopathology*
  • In Vitro Techniques
  • Levetiracetam
  • Membrane Glycoproteins / metabolism
  • Membrane Potentials / drug effects
  • Membrane Potentials / genetics
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Nerve Tissue Proteins / metabolism
  • Neurons / drug effects
  • Patch-Clamp Techniques
  • Piracetam / analogs & derivatives*
  • Piracetam / pharmacology
  • Potassium Channel Blockers / pharmacology
  • Synapsins / deficiency*
  • Synaptophysin / metabolism

Substances

  • Anticonvulsants
  • Membrane Glycoproteins
  • Nerve Tissue Proteins
  • Potassium Channel Blockers
  • Sv2a protein, mouse
  • Sv2b protein, mouse
  • Synapsins
  • Synaptophysin
  • Levetiracetam
  • 4-Aminopyridine
  • Piracetam